Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography–tandem mass spectrometry
- 21 August 2009
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 877 (29) , 3506-3514
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: The NOBORI PK studyCatheterization and Cardiovascular Interventions, 2008
- Drug-Eluting or Bare-Metal Stents for Acute Myocardial InfarctionNew England Journal of Medicine, 2008
- Evaluation of a Deuterium-Labeled Internal Standard for the Measurement of Sirolimus by High-Throughput HPLC Electrospray Ionization Tandem Mass SpectrometryClinical Chemistry, 2008
- Differential Effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary VasomotionJACC, 2008
- Drug-eluting stents—what should be improved?Annals of Medicine, 2008
- Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimusJournal of Mass Spectrometry, 2007
- Angiographic Results of the First Human Experience With the Biolimus A9 Drug-Eluting Stent for De Novo Coronary LesionsThe American Journal of Cardiology, 2006
- Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesionsCatheterization and Cardiovascular Interventions, 2005
- Sirolimus-Eluting Coronary StentsNew England Journal of Medicine, 2002
- High Performance Liquid Chromatographic Isolation, Spectroscopic Characterization, and Immunosuppressive Activities of Two Rapamycin Degradation ProductsJournal of Liquid Chromatography, 1994